What is HC Wainwright's Estimate for Myomo FY2026 Earnings?

Myomo, Inc. (NYSEAMERICAN:MYO - Free Report) - Equities researchers at HC Wainwright dropped their FY2026 EPS estimates for Myomo in a note issued to investors on Wednesday, March 12th. HC Wainwright analyst S. Lee now expects that the company will post earnings of $0.00 per share for the year, down from their prior forecast of $0.05. HC Wainwright has a "Buy" rating and a $9.50 price objective on the stock. The consensus estimate for Myomo's current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Myomo's FY2028 earnings at $0.42 EPS and FY2029 earnings at $0.60 EPS.

Other research analysts have also recently issued reports about the stock. Alliance Global Partners reissued a "buy" rating on shares of Myomo in a research report on Tuesday, March 11th. Craig Hallum boosted their target price on shares of Myomo from $9.00 to $11.00 and gave the stock a "buy" rating in a research report on Tuesday, March 11th. Finally, Ascendiant Capital Markets boosted their target price on shares of Myomo from $9.00 to $11.00 and gave the stock a "buy" rating in a research report on Monday. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $9.75.

Myomo Stock Down 2.4 %

MYO stock traded down $0.13 during midday trading on Friday, reaching $5.31. 569,341 shares of the company's stock traded hands, compared to its average volume of 336,184. Myomo has a fifty-two week low of $2.51 and a fifty-two week high of $7.17. The stock has a market cap of $160.63 million, a price-to-earnings ratio of -23.09 and a beta of 1.68.

Remove Ads

Insider Buying and Selling

In other Myomo news, Director Thomas F. Kirk bought 7,400 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were bought at an average price of $5.00 per share, for a total transaction of $37,000.00. Following the acquisition, the director now directly owns 255,933 shares of the company's stock, valued at approximately $1,279,665. This trade represents a 2.98 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Harry Kovelman sold 30,000 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $5.50, for a total value of $165,000.00. Following the completion of the transaction, the insider now owns 97,973 shares in the company, valued at $538,851.50. This represents a 23.44 % decrease in their position. The disclosure for this sale can be found here. Insiders own 4.54% of the company's stock.

Institutional Investors Weigh In On Myomo

Large investors have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP boosted its position in shares of Myomo by 60.8% in the third quarter. GSA Capital Partners LLP now owns 103,342 shares of the company's stock valued at $414,000 after acquiring an additional 39,085 shares during the period. Stonepine Capital Management LLC acquired a new position in Myomo during the third quarter worth $401,000. Jane Street Group LLC acquired a new position in Myomo during the third quarter worth $65,000. XTX Topco Ltd acquired a new position in Myomo during the third quarter worth $149,000. Finally, Barclays PLC acquired a new position in Myomo during the third quarter worth $36,000. Institutional investors own 44.99% of the company's stock.

Myomo Company Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.